Experienced in Tetanus

Dr. George J. Alangaden

Infectious Disease
Henry Ford Health System
2799 W Grand Blvd, 
Detroit, MI 
Accepting New Patients
Offers Telehealth
Experienced in Tetanus
Henry Ford Health System
2799 W Grand Blvd, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

George Alangaden is an Infectious Disease provider in Detroit, Michigan. Dr. Alangaden is rated as an Experienced provider by MediFind in the treatment of Tetanus. His top areas of expertise are Sepsis, Cytomegalovirus Infection, Cytomegalic Inclusion Disease, and COVID-19. Dr. Alangaden is currently accepting new patients.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Tetanus.

Specialties
Infectious Disease
Licenses
Internal Medicine in FM
Hospital Affiliations
Henry Ford Allegiance Health
Henry Ford Health Hospital
Henry Ford Macomb Hospital
Languages Spoken
English
Hindi
Malayalam
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HENRY FORD HEALTH SYSTEM
2799 W Grand Blvd, Detroit, MI 48202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
T2Bacteria Panel Pivotal Study
T2Bacteria Panel Pivotal Study
Enrollment Status: Completed
Publish Date: August 17, 2018
View 3 Less Clinical Trials

79 Total Publications

Is Shorter Better in Oncology Patients, Too? A Retrospective Cohort Study of Short- Versus Long-Course Antibiotic Therapy for Uncomplicated Infections in Solid Tumor Patients Receiving Care in Ambulatory Oncology Clinics.
Is Shorter Better in Oncology Patients, Too? A Retrospective Cohort Study of Short- Versus Long-Course Antibiotic Therapy for Uncomplicated Infections in Solid Tumor Patients Receiving Care in Ambulatory Oncology Clinics.
Journal: Open forum infectious diseases
Published: April 11, 2025
Similar Doctors
Experienced in Tetanus
Dr. Laura E. Power
Infectious Disease | Public Health and Preventive Medicine
Experienced in Tetanus
Dr. Laura E. Power
Infectious Disease | Public Health and Preventive Medicine
1500 East Medical Center Drive, 3rd Floor Taubman Center Recp D, 
Ann Arbor, MI 
 (33.4 miles away)
734-647-5899
Languages Spoken:
English
See accepted insurances

Laura Power is an Infectious Disease specialist and a Public Health and Preventive Medicine provider in Ann Arbor, Michigan. Dr. Power is rated as an Experienced provider by MediFind in the treatment of Tetanus. Her top areas of expertise are Tetanus, Severe Acute Respiratory Syndrome (SARS), Pneumonia, and Osteomyelitis in Children.

Experienced in Tetanus
Dr. Navina K. Birk
Infectious Disease | Hospital Medicine
Experienced in Tetanus
Dr. Navina K. Birk
Infectious Disease | Hospital Medicine

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (0.1 miles away)
313-876-2573
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Navina Birk is an Infectious Disease specialist and a Hospital Medicine provider in Detroit, Michigan. Dr. Birk is rated as an Experienced provider by MediFind in the treatment of Tetanus. Her top areas of expertise are Tetanus and Shingles. Dr. Birk is currently accepting new patients.

Experienced in Tetanus
Dr. Indira A. Brar
Infectious Disease
Experienced in Tetanus
Dr. Indira A. Brar
Infectious Disease

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (0.1 miles away)
313-876-2573
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Indira Brar is an Infectious Disease provider in Detroit, Michigan. Dr. Brar is rated as a Distinguished provider by MediFind in the treatment of Tetanus. Her top areas of expertise are HIV/AIDS, COVID-19, Myelitis, and AIDS Dysmorphic Syndrome. Dr. Brar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alangaden's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile